Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 28

1.

Expression of Syk and MAP4 proteins in ovarian cancer.

Zhang S, Deen S, Storr SJ, Yao A, Martin SG.

J Cancer Res Clin Oncol. 2019 Apr;145(4):909-919. doi: 10.1007/s00432-019-02856-9. Epub 2019 Feb 8.

2.

Calpain system protein expression and activity in ovarian cancer.

Zhang S, Deen S, Storr SJ, Chondrou PS, Nicholls H, Yao A, Rungsakaolert P, Martin SG.

J Cancer Res Clin Oncol. 2019 Feb;145(2):345-361. doi: 10.1007/s00432-018-2794-2. Epub 2018 Nov 17.

3.

MyD88 and TLR4 Expression in Epithelial Ovarian Cancer.

Block MS, Vierkant RA, Rambau PF, Winham SJ, Wagner P, Traficante N, Tołoczko A, Tiezzi DG, Taran FA, Sinn P, Sieh W, Sharma R, Rothstein JH, Ramón Y Cajal T, Paz-Ares L, Oszurek O, Orsulic S, Ness RB, Nelson G, Modugno F, Menkiszak J, McGuire V, McCauley BM, Mack M, Lubiński J, Longacre TA, Li Z, Lester J, Kennedy CJ, Kalli KR, Jung AY, Johnatty SE, Jimenez-Linan M, Jensen A, Intermaggio MP, Hung J, Herpel E, Hernandez BY, Hartkopf AD, Harnett PR, Ghatage P, García-Bueno JM, Gao B, Fereday S, Eilber U, Edwards RP, de Sousa CB, de Andrade JM, Chudecka-Głaz A, Chenevix-Trench G, Cazorla A, Brucker SY; Australian Ovarian Cancer Study Group, Alsop J, Whittemore AS, Steed H, Staebler A, Moysich KB, Menon U, Koziak JM, Kommoss S, Kjaer SK, Kelemen LE, Karlan BY, Huntsman DG, Høgdall E, Gronwald J, Goodman MT, Gilks B, García MJ, Fasching PA, de Fazio A, Deen S, Chang-Claude J, Candido Dos Reis FJ, Campbell IG, Brenton JD, Bowtell DD, Benítez J, Pharoah PDP, Köbel M, Ramus SJ, Goode EL.

Mayo Clin Proc. 2018 Mar;93(3):307-320. doi: 10.1016/j.mayocp.2017.10.023.

4.

High mobility group protein B1 is a predictor of poor survival in ovarian cancer.

Machado LR, Moseley PM, Moss R, Deen S, Nolan C, Spendlove I, Ramage JM, Chan SY, Durrant LG.

Oncotarget. 2017 Aug 24;8(60):101215-101223. doi: 10.18632/oncotarget.20538. eCollection 2017 Nov 24.

5.

Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer.

Ovarian Tumor Tissue Analysis (OTTA) Consortium, Goode EL, Block MS, Kalli KR, Vierkant RA, Chen W, Fogarty ZC, Gentry-Maharaj A, Tołoczko A, Hein A, Bouligny AL, Jensen A, Osorio A, Hartkopf A, Ryan A, Chudecka-Głaz A, Magliocco AM, Hartmann A, Jung AY, Gao B, Hernandez BY, Fridley BL, McCauley BM, Kennedy CJ, Wang C, Karpinskyj C, de Sousa CB, Tiezzi DG, Wachter DL, Herpel E, Taran FA, Modugno F, Nelson G, Lubiński J, Menkiszak J, Alsop J, Lester J, García-Donas J, Nation J, Hung J, Palacios J, Rothstein JH, Kelley JL, de Andrade JM, Robles-Díaz L, Intermaggio MP, Widschwendter M, Beckmann MW, Ruebner M, Jimenez-Linan M, Singh N, Oszurek O, Harnett PR, Rambau PF, Sinn P, Wagner P, Ghatage P, Sharma R, Edwards RP, Ness RB, Orsulic S, Brucker SY, Johnatty SE, Longacre TA, Ursula E, McGuire V, Sieh W, Natanzon Y, Li Z, Whittemore AS, Anna A, Staebler A, Karlan BY, Gilks B, Bowtell DD, Høgdall E, Candido dos Reis FJ, Steed H, Campbell IG, Gronwald J, Benítez J, Koziak JM, Chang-Claude J, Moysich KB, Kelemen LE, Cook LS, Goodman MT, García MJ, Fasching PA, Kommoss S, Deen S, Kjaer SK, Menon U, Brenton JD, Pharoah PDP, Chenevix-Trench G, Huntsman DG, Winham SJ, Köbel M, Ramus SJ.

JAMA Oncol. 2017 Dec 1;3(12):e173290. doi: 10.1001/jamaoncol.2017.3290.

6.

Sterol regulatory element binding protein-1 (SREBP1) gene expression is similarly increased in polycystic ovary syndrome and endometrial cancer.

Shafiee MN, Mongan N, Seedhouse C, Chapman C, Deen S, Abu J, Atiomo W.

Acta Obstet Gynecol Scand. 2017 May;96(5):556-562. doi: 10.1111/aogs.13106. Epub 2017 Mar 16.

PMID:
28176325
7.

The day we started HPV triage.

Deen S, Vreynhoef S, Gandhi N, Juliana A, Nunns D, O'Neill D.

J Clin Pathol. 2016 Sep;69(9):822-5. doi: 10.1136/jclinpath-2015-203527. Epub 2016 Mar 30.

PMID:
27030306
8.

Up-regulation of genes involved in the insulin signalling pathway (IGF1, PTEN and IGFBP1) in the endometrium may link polycystic ovarian syndrome and endometrial cancer.

Shafiee MN, Seedhouse C, Mongan N, Chapman C, Deen S, Abu J, Atiomo W.

Mol Cell Endocrinol. 2016 Mar 15;424:94-101. doi: 10.1016/j.mce.2016.01.019. Epub 2016 Jan 21.

PMID:
26802879
9.

Combined image and genomic analysis of high-grade serous ovarian cancer reveals PTEN loss as a common driver event and prognostic classifier.

Martins FC, Santiago Id, Trinh A, Xian J, Guo A, Sayal K, Jimenez-Linan M, Deen S, Driver K, Mack M, Aslop J, Pharoah PD, Markowetz F, Brenton JD.

Genome Biol. 2014 Dec 17;15(12):526. doi: 10.1186/s13059-014-0526-8.

10.

Data Mining of Gene Arrays for Biomarkers of Survival in Ovarian Cancer.

Coveney C, Boocock DJ, Rees RC, Deen S, Ball GR.

Microarrays (Basel). 2015 Jul 17;4(3):324-38. doi: 10.3390/microarrays4030324.

11.

Preventing endometrial cancer risk in polycystic ovarian syndrome (PCOS) women: could metformin help?

Shafiee MN, Khan G, Ariffin R, Abu J, Chapman C, Deen S, Nunns D, Barrett DA, Seedhouse C, Atiomo W.

Gynecol Oncol. 2014 Jan;132(1):248-53. doi: 10.1016/j.ygyno.2013.10.028. Epub 2013 Oct 30. Review.

PMID:
24183733
12.

Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study.

Sieh W, Köbel M, Longacre TA, Bowtell DD, deFazio A, Goodman MT, Høgdall E, Deen S, Wentzensen N, Moysich KB, Brenton JD, Clarke BA, Menon U, Gilks CB, Kim A, Madore J, Fereday S, George J, Galletta L, Lurie G, Wilkens LR, Carney ME, Thompson PJ, Matsuno RK, Kjær SK, Jensen A, Høgdall C, Kalli KR, Fridley BL, Keeney GL, Vierkant RA, Cunningham JM, Brinton LA, Yang HP, Sherman ME, García-Closas M, Lissowska J, Odunsi K, Morrison C, Lele S, Bshara W, Sucheston L, Jimenez-Linan M, Driver K, Alsop J, Mack M, McGuire V, Rothstein JH, Rosen BP, Bernardini MQ, Mackay H, Oza A, Wozniak EL, Benjamin E, Gentry-Maharaj A, Gayther SA, Tinker AV, Prentice LM, Chow C, Anglesio MS, Johnatty SE, Chenevix-Trench G, Whittemore AS, Pharoah PD, Goode EL, Huntsman DG, Ramus SJ.

Lancet Oncol. 2013 Aug;14(9):853-62. doi: 10.1016/S1470-2045(13)70253-5. Epub 2013 Jul 9.

13.

Poly(adenosine diphosphate-ribose) polymerase expression in BRCA-proficient ovarian high-grade serous carcinoma; association with patient survival.

Gan A, Green AR, Nolan CC, Martin S, Deen S.

Hum Pathol. 2013 Aug;44(8):1638-47. doi: 10.1016/j.humpath.2013.01.015. Epub 2013 Apr 8.

PMID:
23574784
14.

Clinical outcome of atypical endometrial hyperplasia diagnosed on an endometrial biopsy: institutional experience and review of literature.

Rakha E, Wong SC, Soomro I, Chaudry Z, Sharma A, Deen S, Chan S, Abu J, Nunns D, Williamson K, McGregor A, Hammond R, Brown L.

Am J Surg Pathol. 2012 Nov;36(11):1683-90. doi: 10.1097/PAS.0b013e31825dd4ff. Review.

PMID:
23073327
15.

Expression of angiogenic chemokines in ovarian clear cell carcinoma.

Quattrocchi L, Sisson M, Green A, Martin SG, Durrant L, Deen S.

J Obstet Gynaecol Res. 2013 Jan;39(1):297-304. doi: 10.1111/j.1447-0756.2012.01949.x. Epub 2012 Jul 29.

PMID:
22845872
16.

Co-expression of VEGF and CA9 in ovarian high-grade serous carcinoma and relationship to survival.

Williams E, Martin S, Moss R, Durrant L, Deen S.

Virchows Arch. 2012 Jul;461(1):33-9. doi: 10.1007/s00428-012-1252-9. Epub 2012 Jun 15.

PMID:
22699808
17.

Comparison of tissue effects quantified histologically between PlasmaJet coagulator and Helica thermal coagulator.

Deb S, Sahu B, Deen S, Newman C, Powell M.

Arch Gynecol Obstet. 2012 Aug;286(2):399-402. doi: 10.1007/s00404-012-2302-x. Epub 2012 Mar 31.

PMID:
22467148
18.

Calpain-2 expression is associated with response to platinum based chemotherapy, progression-free and overall survival in ovarian cancer.

Storr SJ, Safuan S, Woolston CM, Abdel-Fatah T, Deen S, Chan SY, Martin SG.

J Cell Mol Med. 2012 Oct;16(10):2422-8. doi: 10.1111/j.1582-4934.2012.01559.x.

19.

Total Colonic Expulsion with Part of Small Bowel per Vaginum due to Low-Flow Phenomenon and NOMI: A Case Report.

Deen S, Powell M.

Diagn Ther Endosc. 2011;2011:498097. doi: 10.1155/2011/498097. Epub 2011 Apr 3.

20.

The cadherin switch in ovarian high-grade serous carcinoma is associated with disease progression.

Quattrocchi L, Green AR, Martin S, Durrant L, Deen S.

Virchows Arch. 2011 Jul;459(1):21-9. doi: 10.1007/s00428-011-1082-1. Epub 2011 Apr 21.

PMID:
21509572

Supplemental Content

Loading ...
Support Center